January 28, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Unit 2 of Apitoria Pharma Pvt. Ltd., received EIR from US FDA with VAI classification – Reg.,

Ref : Our letter dated September 30, 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-2, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana from September 23 to 27, 2024.

The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI).

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**
Digitally signed by BADDIGAM ADI REDDY
Date: 2025.01.28 09:54:23 +05'30'
B. Adi Reddy
Company Secretary